3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate has been researched along with emtricitabine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alieu, A; Alinde, B; Callebaut, C; Chiodi, F; Else, L; Fox, J; Gray, CM; Herrera, C; Kaleebu, P; Khoo, S; Limakatso, L; Martinson, N; Mugaba, S; Muhumuza, R; Namubiru, P; O'Hagan, K; Odoch, G; Opoka, D; Penchala, SD; Petkov, S; Pillay, AD; Seatlholo, P; Seeley, J; Seiphetlo, TB; Serwanga, J; Ssemata, AS; Webb, EL; Weiss, H | 1 |
1 trial(s) available for 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate and emtricitabine
| Article | Year |
|---|---|
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Topics: Africa South of the Sahara; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Pre-Exposure Prophylaxis | 2023 |